H
Hubei Goto Biopharm Co Ltd
SZSE:300966
Hubei Goto Biopharm Co Ltd
SZSE:300966
Price:
21.8
CNY
0.46%
Market Cap:
¥2.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
H
|
Hubei Goto Biopharm Co Ltd
SZSE:300966
|
CN |
Income Statement
Earnings Waterfall
Hubei Goto Biopharm Co Ltd
Hubei Goto Biopharm Co Ltd
Income Statement
Hubei Goto Biopharm Co Ltd
Hubei Goto Biopharm Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
7
|
7
|
7
|
6
|
5
|
6
|
6
|
8
|
9
|
13
|
14
|
14
|
14
|
13
|
13
|
14
|
17
|
24
|
30
|
0
|
0
|
|
| Revenue |
524
N/A
|
468
-11%
|
573
+22%
|
569
-1%
|
595
+5%
|
591
-1%
|
570
-4%
|
557
-2%
|
592
+6%
|
605
+2%
|
604
0%
|
604
+0%
|
543
-10%
|
566
+4%
|
569
+0%
|
532
-6%
|
547
+3%
|
537
-2%
|
554
+3%
|
605
+9%
|
626
+3%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
(400)
|
(361)
|
(437)
|
(427)
|
(442)
|
(438)
|
(419)
|
(413)
|
(448)
|
(466)
|
(475)
|
(476)
|
(422)
|
(449)
|
(443)
|
(427)
|
(459)
|
(435)
|
(442)
|
(476)
|
(490)
|
|
| Gross Profit |
123
N/A
|
107
-13%
|
136
+27%
|
142
+4%
|
152
+7%
|
153
+0%
|
150
-2%
|
143
-5%
|
144
+1%
|
139
-3%
|
129
-7%
|
128
-1%
|
121
-6%
|
117
-3%
|
127
+8%
|
105
-17%
|
87
-17%
|
101
+16%
|
112
+10%
|
129
+16%
|
136
+5%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(55)
|
(42)
|
(51)
|
(55)
|
(69)
|
(85)
|
(85)
|
(86)
|
(87)
|
(91)
|
(95)
|
(98)
|
(96)
|
(88)
|
(93)
|
(94)
|
(94)
|
(114)
|
(129)
|
(142)
|
(158)
|
|
| Selling, General & Administrative |
(31)
|
(21)
|
(29)
|
(30)
|
(39)
|
(48)
|
(50)
|
(50)
|
(48)
|
(45)
|
(50)
|
(51)
|
(55)
|
(52)
|
(58)
|
(62)
|
(63)
|
(65)
|
(75)
|
(75)
|
(80)
|
|
| Research & Development |
(25)
|
(21)
|
(15)
|
(17)
|
(25)
|
(37)
|
(39)
|
(41)
|
(42)
|
(43)
|
(47)
|
(49)
|
(46)
|
(33)
|
(37)
|
(37)
|
(40)
|
(44)
|
(55)
|
(67)
|
(70)
|
|
| Depreciation & Amortization |
0
|
(3)
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(10)
|
0
|
0
|
0
|
(15)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
3
|
3
|
(7)
|
(7)
|
(6)
|
4
|
5
|
6
|
3
|
3
|
2
|
3
|
4
|
6
|
1
|
5
|
9
|
11
|
2
|
(1)
|
(8)
|
|
| Operating Income |
69
N/A
|
65
-6%
|
86
+33%
|
87
+2%
|
83
-5%
|
68
-18%
|
65
-5%
|
58
-12%
|
57
-1%
|
48
-16%
|
34
-29%
|
30
-11%
|
24
-20%
|
29
+20%
|
33
+14%
|
11
-67%
|
(6)
N/A
|
(12)
-88%
|
(17)
-40%
|
(13)
+25%
|
(22)
-72%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(9)
|
(7)
|
(9)
|
(8)
|
(7)
|
(6)
|
(6)
|
(7)
|
(6)
|
(9)
|
(10)
|
(9)
|
(12)
|
(10)
|
(10)
|
(13)
|
(16)
|
(21)
|
(31)
|
(40)
|
(44)
|
|
| Non-Reccuring Items |
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
(0)
|
(10)
|
(1)
|
(1)
|
(1)
|
|
| Total Other Income |
5
|
4
|
3
|
7
|
8
|
23
|
23
|
17
|
18
|
1
|
4
|
3
|
0
|
2
|
(5)
|
(5)
|
(3)
|
(2)
|
(3)
|
(3)
|
(5)
|
|
| Pre-Tax Income |
65
N/A
|
60
-8%
|
80
+34%
|
87
+8%
|
85
-2%
|
86
+2%
|
82
-5%
|
67
-18%
|
70
+4%
|
39
-45%
|
28
-28%
|
24
-15%
|
13
-46%
|
19
+49%
|
18
-8%
|
(7)
N/A
|
(26)
-290%
|
(46)
-77%
|
(52)
-14%
|
(57)
-11%
|
(73)
-27%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(8)
|
(7)
|
(10)
|
(12)
|
(9)
|
(8)
|
(6)
|
(4)
|
(6)
|
1
|
3
|
6
|
9
|
2
|
3
|
4
|
9
|
14
|
17
|
18
|
20
|
|
| Income from Continuing Operations |
58
|
53
|
70
|
75
|
76
|
78
|
76
|
64
|
64
|
40
|
30
|
29
|
21
|
21
|
21
|
(2)
|
(17)
|
(32)
|
(35)
|
(39)
|
(53)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
3
|
4
|
5
|
6
|
7
|
|
| Net Income (Common) |
58
N/A
|
53
-7%
|
71
+33%
|
76
+7%
|
76
+1%
|
78
+3%
|
76
-3%
|
64
-16%
|
64
0%
|
40
-37%
|
31
-22%
|
31
-2%
|
23
-25%
|
23
0%
|
23
-2%
|
0
-98%
|
(14)
N/A
|
(28)
-98%
|
(30)
-9%
|
(34)
-12%
|
(46)
-36%
|
|
| EPS (Diluted) |
0.66
N/A
|
0.62
-6%
|
0.81
+31%
|
0.72
-11%
|
0.65
-10%
|
0.74
+14%
|
0.68
-8%
|
0.55
-19%
|
0.55
N/A
|
0.35
-36%
|
0.27
-23%
|
0.27
N/A
|
0.2
-26%
|
0.2
N/A
|
0.2
N/A
|
0.01
-95%
|
-0.12
N/A
|
-0.24
-100%
|
-0.26
-8%
|
-0.3
-15%
|
-0.36
-20%
|
|
Switch to:
Switch to:
See Also
Discover More
